drugset / Trial / NCT02139228
Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Evaluate the persistency of immune response against Haemophilus influenzae type b by assessing anti-PRP antibody levels in children vaccinated with either Hib-CRM197 or Hib-TT booster vaccine approximately 4 years before.
Timeline
- Start
- 2014-11
- Primary completion
- 2014-12
- Completion
- 2015-01
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Hib CRM197 vs Hib TT; Vaccine Group Ratios 0.53 (95% CI 0.36 to 0.76); ANOVA NCT02139228 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hib-CRM197 | Vaccine | — | — |
| Comparator | Hib-TT | Vaccine | — | — |